Neuland Laboratories share price
You have to be logged in to add this to Watchlist.- ₹12,702.50(-7.00%)February 13, 2025 15:44:17 PM IST
- NSE
- BSE
- Vol : 48.83K (NSE + BSE)Last 20 day avg : 38.75 K
Neuland Laboratories is trading -7.00% lower at Rs 12,702.50 as compared to its last closing price. Neuland Laboratories has been trading in the price range of 13,717.90 & 12,567.70. Neuland Laboratories has given 3.81% in this year & 0.38% in the last 5 days. Neuland Laboratories has TTM P/E ratio 56.82 as compared to the sector P/E of 28.63.There are 2 analysts who have initiated coverage on Neuland Laboratories. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 101.59 Crores in its last quarter.Listed peers of Neuland Laboratories include Pfizer (0.85%), Astrazeneca Pharma India (-1.46%), Neuland Laboratories (-7.00%).The Mutual Fund holding in Neuland Laboratories was at 6.29% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Neuland Laboratories was at 23.86% in 31 Dec 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Feb 13, 2025, 05:08 PM UTC
- Dividend YieldLower than industry0.10Annual dividends as a percentage of the stock price.
- P/BHigher than historical values14.25The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EExpensive P/E65.36Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.19The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- BetaHigh volatility1.33Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.07The debt-to-equity ratio, indicating a company's financial leverage.
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 1.32% from Rs 398.03 crore to Rs 392.83 crore, year-on-year
- The company has grown its December quarter profit by 24.81% from Rs 81.39 crore to Rs 101.59 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 15,334.90
- R2
- 16,535.65
- R3
- 17,852.30
- S1
- 12,817.50
- S2
- 11,500.85
- S3
- 10,300.10
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Pfizer | Bearish | 4,159.35 | 0.85 | 19,003.40 | 36.40 | 5.54 | 0.80 | 1.51 |
| Astrazeneca Pharma India | Bullish | 7,385.00 | -1.46 | 18,392.63 | 126.60 | 26.73 | 0.32 | 0.39 |
| Neuland Laboratories | Moderately Bearish | 12,702.50 | -7.00 | 16,285.80 | 57.42 | 14.25 | 0.10 | 4.22 |
| Unichem Laboratories | Moderately Bearish | 694.20 | -0.43 | 4,897.45 | - | 2.17 | - | 2.64 |
| Themis Medicare | Bearish | 200.00 | -1.65 | 1,838.88 | 49.19 | 5.66 | 0.22 | 7.09 |
- Promoter(s) holding is moderate at 32.68%
- Promoter(s) have decreased the stake in the company in last 12 months
- Mutual Funds holding has increased by 2.25 percentage points from previous quarter
- FIIs are invested in this company
- FIIs holding has decreased by 2.60 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-10 | Quarterly Results |
| 2024-11-06 | Quarterly Results |
| 2024-08-01 | Quarterly Results |
| 2024-05-10 | Audited Results & Final Dividend |
| 2024-02-08 | Quarterly Results |
- IndustryMajor Drugs
- ISININE794A01010
- BSE Code524558
- NSE CodeNEULANDLAB
Neuland Laboratories is trading at 12702.50 as on Thu Feb 13 2025 10:14:17. This is -7.00% lower as compared to its previous closing price of 13658.50.
The market capitalization of Neuland Laboratories is 16285.80 Cr as on Thu Feb 13 2025 10:14:17.
The average broker rating on Neuland Laboratories is Strong Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Neuland Laboratories is 18089.55 whereas the 52 wk low is 5532.50
Neuland Laboratories can be analyzed on the following key metrics -
- TTM P/E: 56.82
- Sector P/E: 28.63
- Dividend Yield: 0.10%
- D/E ratio: 0.08
Neuland Laboratories reported a net profit of 300.08 Cr in 2024.
The Mutual Fund Shareholding was 6.29% at the end of 31 Dec 2024.